Table 2 Vaccination coverage and test-and-treat requirements to half the number of severe cases at 10% pre-existing vaccination coverage

From: Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs

Country

Re

Vaccination

Test-and-treat

No. of vaccinated individuals per 1,000,000 people

No. of antivirals distributed per 1,000,000 people

Testing rate (tests/100,000 people/day)

Zambia

1.2

496,192

18,436

545

1.5

586,432

60,370

2185

2.0

665,567

113,835

4383

Brazil

1.2

312,095

15,494

316

1.5

437,067

82,093

1760

2.0

566,068

197,465

4751

Georgia

1.2

253,988

9246

166

1.5

317,855

52,499

721

2.0

477,855

211,977

3471

Netherlands

1.2

240,271

8758

206

1.5

319,695

49,952

701

2.0

474,469

394,414

6802

  1. For vaccination, the additional number of individuals per 1,000,000 people that must be vaccinated on top of the 10% pre-existing vaccination coverage is tabulated. For test-and-treat, there are no restrictions on access to symptomatic testing at clinics (i.e., all symptomatic individuals who sought testing at clinics would receive one if in stock) and high-risk household contacts of test-positive individuals are not tested.
Back to article page